Investors

IR Overview

News

Date Title  
Toggle Summary Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung
Toggle Summary Paul Stead Joins Adaptimmune as Vice President of Business Development
PHILADELPHIA, Pa. and OXFORD, England , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead , B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development.
Paul Stead Joins Adaptimmune as Vice President of Business Development
PHILADELPHIA, Pa. and OXFORD, England , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead , B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development.
Toggle Summary Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
PHILADELPHIA and OXFORD, United Kingdom , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
PHILADELPHIA and OXFORD, United Kingdom , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Toggle Summary Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
PHILADELPHIA, Pa. and OXFORD, UK , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
PHILADELPHIA, Pa. and OXFORD, UK , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Toggle Summary Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
PHILADELPHIA, Pa. and OXFORD, UK , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
PHILADELPHIA, Pa. and OXFORD, UK , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of
Toggle Summary Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters summarizing study designs for ongoing clinical trials with MAGE-A4 and NY-ESO SPEAR T-cells at the
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters summarizing study designs for ongoing clinical trials with MAGE-A4 and NY-ESO SPEAR T-cells at the
Toggle Summary NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, released updated data from the ongoing pilot study of NY‑ESO SPEAR T-cells in synovial sarcoma, as well as an overview of study design
NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, released updated data from the ongoing pilot study of NY‑ESO SPEAR T-cells in synovial sarcoma, as well as an overview of study design
Toggle Summary Adaptimmune marks Official Opening of U.K. Headquarters
Flagship Facility is new Base for U.K. Research and Development Operations PHILADELPHIA and OXFORD, U.K. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will host an official opening ceremony at its
Adaptimmune marks Official Opening of U.K. Headquarters
Flagship Facility is new Base for U.K. Research and Development Operations PHILADELPHIA and OXFORD, U.K. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will host an official opening ceremony at its
Toggle Summary Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November 8-12, 2017 at the Gaylord National
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November 8-12, 2017 at the Gaylord National
Toggle Summary Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
PHILADELPHIA and OXFORD, U.K. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be
Toggle Summary Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates
– GlaxoSmithKline plc (LSE/NYSE:GSK) exercised its option to license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program – – Adaptimmune will receive up to $61 million from GSK over the course of the NY-ESO transition period, which extends funding
Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates
– GlaxoSmithKline plc (LSE/NYSE:GSK) exercised its option to license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program – – Adaptimmune will receive up to $61 million from GSK over the course of the NY-ESO transition period, which extends funding
Toggle Summary Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017
PHILADELPHIA and OXFORD, U.K. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2017 before the open of the U.S. markets on Thursday November 2, 2017 .
Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017
PHILADELPHIA and OXFORD, U.K. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2017 before the open of the U.S. markets on Thursday November 2, 2017 .
Toggle Summary Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
PHILADELPHIA and OXFORD, U.K. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has joined the Company as Vice President of Communications and Investor Relations.
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
PHILADELPHIA and OXFORD, U.K. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has joined the Company as Vice President of Communications and Investor Relations.
Toggle Summary James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
PHILADELPHIA and OXFORD, U.K. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink Partners Roundtable Series:
James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
PHILADELPHIA and OXFORD, U.K. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink Partners Roundtable Series:
Toggle Summary GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
PHILADELPHIA and OXFORD, United Kingdom , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
PHILADELPHIA and OXFORD, United Kingdom , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement
Toggle Summary Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
PHILADELPHIA and OXFORD, U.K. , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5 , and Wednesday, September 6
Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
PHILADELPHIA and OXFORD, U.K. , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5 , and Wednesday, September 6
Toggle Summary Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million ; operations funded through to late 2019 –        – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different
Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million ; operations funded through to late 2019 –        – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different
Toggle Summary Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
PHILADELPHIA and OXFORD, United Kingdom , July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017.
Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
PHILADELPHIA and OXFORD, United Kingdom , July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017.
Toggle Summary From the Desk of James Noble - Congratulations to Novartis on Winning FDA Panel Backing for its CAR T Therapy
On Tuesday July 12th, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) unanimously endorsed Novartis’s anti-CD19 CAR-T therapy (tisagenlecleucel, “CTL019”). This was a significant milestone in realizing the promise of engineered T-cell therapy, and it is likely that
From the Desk of James Noble - Congratulations to Novartis on Winning FDA Panel Backing for its CAR T Therapy
On Tuesday July 12th, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) unanimously endorsed Novartis’s anti-CD19 CAR-T therapy (tisagenlecleucel, “CTL019”). This was a significant milestone in realizing the promise of engineered T-cell therapy, and it is likely that
Toggle Summary Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom , June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four trials in progress
Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom , June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four trials in progress
Toggle Summary Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom , May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois
Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom , May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois
Toggle Summary Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom , May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with KEYTRUDA® (pembrolizumab),
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom , May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with KEYTRUDA® (pembrolizumab),
Toggle Summary Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, U.K. , May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors.
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, U.K. , May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors.
Toggle Summary Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, U.K. , May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, U.K. , May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular
Toggle Summary Adaptimmune Reports First Quarter 2017 Financial Results
– Offerings in March and April raised net proceeds of $103.2 million ; operations funded through to late 2019 – – Initiated study with wholly-owned AFP SPEAR T-cells – – Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and
Adaptimmune Reports First Quarter 2017 Financial Results
– Offerings in March and April raised net proceeds of $103.2 million ; operations funded through to late 2019 – – Initiated study with wholly-owned AFP SPEAR T-cells – – Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and
Toggle Summary Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
PHILADELPHIA and OXFORD, U.K. , May 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on Wednesday May 10, 2017 .
Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
PHILADELPHIA and OXFORD, U.K. , May 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on Wednesday May 10, 2017 .
Toggle Summary Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K. , May 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank 42 nd Annual Health Care
Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K. , May 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank 42 nd Annual Health Care
Toggle Summary Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
PHILADELPHIA and OXFORD, U.K. , April 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”)
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
PHILADELPHIA and OXFORD, U.K. , April 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”)
Toggle Summary Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , April 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”)
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , April 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”)
Toggle Summary Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
PHILADELPHIA and OXFORD, United Kingdom , March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl , Adaptimmune’s Chief Technology
Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
PHILADELPHIA and OXFORD, United Kingdom , March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl , Adaptimmune’s Chief Technology
Toggle Summary Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
PHILADELPHIA and OXFORD, UK , March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
PHILADELPHIA and OXFORD, UK , March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).
Toggle Summary Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”)
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”)
Toggle Summary Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.
Toggle Summary Adaptimmune Broadens Executive Team
PHILADELPHIA and OXFORD, United Kingdom , March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin , Ph.D., M.B.A, to
Adaptimmune Broadens Executive Team
PHILADELPHIA and OXFORD, United Kingdom , March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin , Ph.D., M.B.A, to
Toggle Summary Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications – – Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation for NY-ESO SPEAR T-cell – – Received FDA notification of permission to proceed with new
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications – – Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation for NY-ESO SPEAR T-cell – – Received FDA notification of permission to proceed with new
Toggle Summary Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
PHILADELPHIA and OXFORD, United Kingdom , March 08, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ended December 31, 2016 before the open of the U.S.
Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
PHILADELPHIA and OXFORD, United Kingdom , March 08, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ended December 31, 2016 before the open of the U.S.
Toggle Summary Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37 th Annual Health
Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37 th Annual Health
Toggle Summary Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia
Company Officially Opens Doors to New Base for Clinical and Manufacturing Operations PHILADELPHIA and OXFORD, United Kingdom , March 01, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc . (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting
Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia
Company Officially Opens Doors to New Base for Clinical and Manufacturing Operations PHILADELPHIA and OXFORD, United Kingdom , March 01, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc . (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting
Toggle Summary Adaptimmune to Participate in Upcoming Investor Conference
PHILADELPHIA and OXFORD, U.K. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Adaptimmune’s Chief Financial Officer, will present at the Leerink 6 th Annual Global Healthcare
Adaptimmune to Participate in Upcoming Investor Conference
PHILADELPHIA and OXFORD, U.K. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Adaptimmune’s Chief Financial Officer, will present at the Leerink 6 th Annual Global Healthcare
Toggle Summary Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley , Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development. Dr.
Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley , Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development. Dr.
Toggle Summary Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME (preferentially expressed antigen in
Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME (preferentially expressed antigen in
Toggle Summary Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US Food and Drug Administration ( FDA ) has accepted the Company’s investigational new drug (IND) application
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, United Kingdom , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US Food and Drug Administration ( FDA ) has accepted the Company’s investigational new drug (IND) application
Toggle Summary Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom and HOUSTON, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for
Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom and HOUSTON, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for
Toggle Summary Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
PHILADELPHIA and OXFORD, United Kingdom , Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY‑ESO SPEAR™ T‑cells in myxoid/round cell liposarcoma (MRCLS).
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
PHILADELPHIA and OXFORD, United Kingdom , Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY‑ESO SPEAR™ T‑cells in myxoid/round cell liposarcoma (MRCLS).
Toggle Summary Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation with updated data on its study of NY‑ESO SPEAR™ (Specific Peptide Enhanced Affinity Receptor)
Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation with updated data on its study of NY‑ESO SPEAR™ (Specific Peptide Enhanced Affinity Receptor)
Toggle Summary Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the presentation of data at the 2016 Society for Immunotherapy for Cancer ( SITC ) annual meeting.
Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the presentation of data at the 2016 Society for Immunotherapy for Cancer ( SITC ) annual meeting.
Toggle Summary Adaptimmune Reports Third Quarter 2016 Financial Results
– U.S. Food and Drug Administration ( FDA ) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells – – Initiated
Adaptimmune Reports Third Quarter 2016 Financial Results
– U.S. Food and Drug Administration ( FDA ) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells – – Initiated
Toggle Summary Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the planned study of its NY‑ESO
Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the planned study of its NY‑ESO
Toggle Summary Adaptimmune Announces Appointment of Tal Zaks to Board of Directors
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment of Tal Zaks , M.D., Ph.D., to its Board of Directors as an independent Non-Executive Director effective
Adaptimmune Announces Appointment of Tal Zaks to Board of Directors
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment of Tal Zaks , M.D., Ph.D., to its Board of Directors as an independent Non-Executive Director effective
Toggle Summary Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters  at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from
Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters  at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from